Aurigene Pharmaceutical Services announces plans for biologics CDMO capacity expansion through new biomanufacturing facility
Introduction:
Aurigene Pharmaceutical Services invests $40 million USD in an R&D and pilot scale facility, while also securing exclusive access to large-scale GMP commercial manufacturing capacity, including fill-finish capabilities.
Features:
Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy's Laboratories, is constructing a cutting-edge development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
Designed with a state-of-the-art concept, the facility provides maximum flexibility for a multi-product, multi-platform approach.
Aurigene's strong foundation in biotherapeutics discovery enhances the company's ability to accelerate the journey of R&D-driven (bio) pharma companies in bringing biologics to the market.
The facility aims to meet the process development and clinical supply requirements of global biotech companies, offering a wide range of services across therapeutic proteins, antibodies, and viral vectors.
The company offers end-to-end and high-quality services for antibodies, proteins, and viral vectors, supported by a dedicated scientific team with a successful track record of commercializing biosimilars globally.
Aurigene has extensive global regulatory experience, ensuring compliance with regulatory standards.
The expansion provides global customers with access to a dedicated team and modern labs, including a pilot facility.
With a proven track record of commercializing six biosimilars globally, Aurigene's team is well-positioned to assist clients in expediting the development of novel biologic drugs for patients.
The facility is expected to be fully operational by the first half of 2024.
An additional fill-finish line is under construction and expected to be validated before the end of 2024.
Specifications:
Name: Aurigene Pharmaceutical Services Limited
Type: Expansion
Year: 2024
